Amicus filings joined by more than 70 diverse entities ranging from manufacturers to patient advocacy groups highlight widespread concern that California courts will adopt an expansive new theory of liability based on a “duty to innovate” that filers say will upend existing products liability law, disincentivize innovation, increase drug prices, and harm patients.